With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
On the heels of DESTINY-Breast04, the FDA approved trastuzumab deruxtecan for HER2-low breast cancer–a new categorization reclassifying 60% of formerly HER2-negative breast cancers that historically had little options outside chemo or endocrine therapy. | FDA 2022
Comments
Post a Comment